Perrigo (PRGO)
(Delayed Data from NYSE)
$31.27 USD
+0.04 (0.13%)
Updated Apr 25, 2024 04:00 PM ET
5-Strong Sell of 5 5
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
PRGO 31.27 +0.04(0.13%)
Will PRGO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRGO
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
PRGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics
Ahead of Perrigo (PRGO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for PRGO
Perrigo’s Strategic Divestiture Prompts Buy Rating from Analyst Susan Anderson
Tourlite Capital Q1 2024 Investor Letter
Perrigo gets offer to sell its HRA Pharma rare diseases unit
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo to sell HRA Pharma Rare Diseases business for EUR 275M